Bionews launches free IgA nephropathy news and community site

Bionews has launched IgA Nephropathy News, a free platform for the estimated 200,000 people in the U.S. living with IgA nephropathy and their caregivers. The site arrives as six FDA approvals since 2021 and ongoing Phase 3 trials have made treatment decisions more complex.

Why it matters: - IgA nephropathy affects an estimated 200,000 people in the U.S., creating a large audience for condition-specific information and peer support. - Treatment choices have multiplied quickly, with six FDA approvals since 2021 and several experimental therapies in Phase 3 trials. - Patients now face more decisions about kidney protection, clinical trials and care planning between appointments.

What happened: - Bionews launched IgA Nephropathy News on Oct. 20, 2026. - The platform is free and built for people living with IgA nephropathy and their caregivers. - Bionews said the community will cover news, personal stories, resource guides and discussion forums. - The site is available at IgA Nephropathy News.

The details: - News Coverage will deliver weekly reporting on IgAN research, clinical trials, regulatory decisions and treatment access. - Columns will feature first-person writing from people living with IgAN and caregivers, with topics including diagnosis, treatment choices, dialysis, transplant, work and family. - Resource Guides will offer disease management and lifestyle information. - Forums are planned for November 2026 and will include moderated discussion boards. - Members will be able to ask questions and compare experiences with treatments, trials and care teams. - IgAN is the most common primary glomerulonephritis worldwide. - The disease is often diagnosed in younger adults. - Many patients will progress to kidney failure within their lifetime.

Between the lines: - The launch positions Bionews to fill an information gap as the IgAN treatment landscape becomes more crowded. - Lauren Hannon, SVP of Strategy & Audience Growth at Bionews, said the company builds rare disease communities with the people who live in them. - Hannon said the site is meant to give patients reporting written for their condition and a place to hear from others who have already made similar choices. - Ariana Barton, a columnist living with IgAN, said she struggled to find relatable stories after her diagnosis and wanted to know whether an ordinary life was still possible.

What's next: - Moderated forums are scheduled to launch in November 2026. - Bionews plans to keep adding reporting and community features as more therapies and trials enter the IgAN space. - More information is available on Bionews on LinkedIn.

The bottom line: - Bionews is betting that patients with IgA nephropathy need both timely reporting and peer advice as treatment options continue to expand.